N4 PHARMA PLC — Major Shareholding Notification 2016

Aug 3, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1066G

Verona Pharma PLC

03 August 2016

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify) :
3. Full name of person(s) subject to the notification obligation: iii	ARIX BIOSCIENCE HOLDINGS LTD & WALES LIFE SCIENCES INVESTMENT FUND LP 'AFFILIATED' ENTITIES
4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v	28 JULY 2016
6. Date on which issuer notified:	29 JULY 2016
7. Threshold(s) that is/are crossed or reached: vi, vii	10.6%

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of  voting rights x
Direct	Direct xi	Indirect  xr r	Direct	Indirect
ORDINARY	207 ,500,000	207,500,000	272,017,620	272,017,620
10.6%

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date XI II	Exercise/ Conversion Period xrv	Number of voting rights that may be acquired if the instrument is exercised! converted.	%of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments XV, XV i
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date XV II	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	%of voting rights xix, XX
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
272,017,620	10.6%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Wales Life Sciences Investment Fund LP previously held 20.55%, it now holds 8.1% as stand alone entity.

Arix Bioscience Holdings Ltd previously held 0%, it now holds 2.5% as a stand-alone entity following the new share issue.

Combined holding 10.6%

Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting  rights:

13. Additional information:
14. Contact name:
15. Contact telephone  number:

Note: Annex should only be submitted to the FCA not the issuer

Annex:  Notification of major interests  in shares xx ll

A: Identity of the persons or legal entity subject to the notification obligation
Full name (including legal form of legal entities)	Arix Bioscience Holdings Ltd Wales Life Sciences Investment Fund LP
Contact address (registered office for legal entities)	20 Berkeley Square London W1J 6EQ
Phone number & email	020-7290-1050
Other useful information (at least legal representative for legal persons)

8: Identity of the notifier, if applicable
Full name	James Rawlingson
Contact address	20 Berkeley Square London W1J 6EQ
Phone number & email	020-7290-1050 lnfo@arixbioscience .com
Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUGUAARUPQUMW